Does a pharmaceutical company have a moral obligation to acknowledge my participation with an ongoing supply of the product that I helped test?
When I learned this summer that the clinical trial of the cancer drug that … Read more
By Anne Harding
New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials.
Overall, 55% of patients offered trial participation agreed to enroll, and white and Black patients agreed to … Read more
By Angus Liu
Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more
By Jason M. Broderick
An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more